Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-09-13 00:05 |
Cantargia: New positive interim results on nadunolimab combination therapy in N…
|
English | 212.4 KB | ||
| 2021-09-13 00:05 |
Cantargia: Nya positiva interimsdata för kombinationsterapi med nadunolimab i N…
|
Swedish | 209.0 KB | ||
| 2021-09-10 13:30 |
Cantargia erhåller regulatoriskt godkännande att påbörja den kliniska studien C…
|
Swedish | 197.4 KB | ||
| 2021-09-10 13:30 |
Cantargia receives regulatory approval to start CESTAFOUR clinical study with n…
|
English | 195.0 KB | ||
| 2021-09-06 16:45 |
Cantargia expanderar utvecklingen av nadunolimab i icke-skivepitel-NSCLC
|
Swedish | 204.6 KB | ||
| 2021-09-06 16:45 |
Cantargia expands nadunolimab development in non-squamous NSCLC
|
English | 203.1 KB | ||
| 2021-09-01 09:00 |
Cantargia förstärker bolagets ledningsgrupp
|
Swedish | 187.2 KB | ||
| 2021-09-01 09:00 |
Cantargia strengthens the company management team
|
English | 189.1 KB | ||
| 2021-08-30 14:30 |
Cantargia reports preclinical data highlighting advantages of nadunolimab mecha…
|
English | 217.8 KB | ||
| 2021-08-30 14:30 |
Cantargia rapporterar prekliniska data som påvisar fördelarna med nadunolimabs …
|
Swedish | 220.4 KB | ||
| 2021-08-26 13:00 |
Cantargia reports first patient treated in CAPAFOUR study investigating combina…
|
English | 192.3 KB | ||
| 2021-08-26 13:00 |
Cantargia rapporterar behandling av första patienten i CAPAFOUR-studien som utv…
|
Swedish | 196.2 KB | ||
| 2021-08-19 11:30 |
Cantargia expands CIRIFOUR trial after successful completion of recruitment in …
|
English | 194.6 KB | ||
| 2021-08-19 11:30 |
Cantargia expanderar CIRIFOUR-studien efter avslutad rekrytering till kombinati…
|
Swedish | 197.8 KB | ||
| 2021-08-19 08:30 | Swedish | 782.6 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
